Prevention of thromboembolism in AF ACC/AHA/ESC Guidelines Jin-Bae Kim, MD, PhD Arrhythmia Service, Division of Cardiology Cardiovascular Center, Kyung.

Slides:



Advertisements
Similar presentations
Antithrombotic Therapy for Stroke Prevention in Atrial Fibrillation.
Advertisements

Atrial Fibrillation Cardiovascular ISCEE 26th October 2010.
1 GRASP-AF Audit - Intro 8 th July 2010 Mark Gregory.
New Atrial Fibrillation/Flutter Pathway and GRASP Tool
Emergency/Urgent Referral* (3) -Pt acutely unwell with palpitations -Pt with haemodyanically unstable acute onset AF -2 nd /3 rd heart block -Exercise.
Atrial Fibrillation Service
Screening and diagnosis of AF and stratifying stroke risk.
Stratifying stroke risk to guide antithrombotic therapy in patients with AF.
JOURNAL REVIEW Newer Antithrombotics in AF 1 Dr Ranjith MP Senior Resident Department of Cardiology Government Medical college Kozhikode.
Atrial fibrillation Cardiology #2 Gimadeeva A.D..
Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines COMBINATION WARFARIN + ASA THERAPY WHEN: TO USE, TO CONSIDER,
Atrial fibrillation.
CLINICAL CASES.
Cerebrovascular prevention in cardiac failure George Ntaios University of Thessaly, Larissa, Greece Lausanne 6/09/2012.
Stroke prevention in atrial fibrillation
European Heart Journal (2006):27, Joint ESC/ACC/AHA Guidelines 2006 Developed in collaboration with the European Heart Rhythm Association (EHRA)
ARISTOTLE TRIAL Dr R Nyabadza GPST1 Ward 32. Structure AF, stroke and CHA 2 -DS 2 VASC Anticoagulant choices ARISTOTLE trial Cost NICE guidance and the.
AF and NOACs An UPDATE JULY 2014
Atrial fibrillation wavelets propagating in different directions disorganised atrial depolarisation without effective atrial contraction f waves
Arrhythmias: The Good, the Bad and the Ugly
Atrial Fibrillation Steve McGlynn
Atrial Fibrillation Steve McGlynn Specialist Principal Pharmacist (Cardiology), Greater Glasgow and Clyde Honorary Clinical Lecture, University of Strathclyde.
NILOFAR RAHMAN, MD AMIT KUMAR, MD. DEFINITION  A SVT with uncoordinated atrial activation with constant deterioration of atrial mechanical function 
Cardioversion of Atrial Fibrillation Clinical Issues Christopher Granger, MD Director, Cardiac Care Unit Duke University Medical Center December 2007.
Atrial Fibrillation. Statistics 1.5% of people over 65 have AF 1.5% of people over 65 have AF 5x increased risk of stroke 5x increased risk of stroke.
Clinical Title Date Jaret Tyler, MD Clinical Cardiac Electrophysiologist Assistant Professor of Medicine Ohio State’s Heart and Vascular Center Atrial.
Improving Stroke Prevention in Patients With Atrial Fibrillation.
APIXABAN NELLA SPAF 21 maggio 2015 ROMA Dott. Sergio Agosti Cardiologo, Ospedale Novi Ligure (AL)
Atrial Fibrillation Warfarin and its newer alternatives
  Warfarin Dabigatran Rivaroxaban Apixaban Edoxaban Target
Dr Avinash Haridas Pillai
The imminent NICE guidelines for AF – what are the implications? David Hargroves, Consultant Physician, Clinical Lead for Stroke Medicine, East Kent Hospitals.
Secondary prevention after a TIA or ischemic stroke.
Atrial Fibrillation Dr Nidhi Bhargava 8/10/13.
Perioperative management of atrial fibrillation
Atrial Fibrillation Andreas Stein Robert Smith, M.D. August 11, 2003.
Atrial Fibrillation Current Management Strategies.
Atrial Fibrillation Now and Then Min-Yen Han,M.D. November 15,2014.
Atrial Fibrillation What is New in the 2006 ACC/AHA/ESC Guidelines HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation. May 2007.
ACTIVE Clopidogrel plus Aspirin versus Aspirin in Patients Unsuitable for Warfarin.
Accuracy of CHADS2, CHA2DS2- VASC and HAS-BLED scores in evaluation of stroke and bleeding risk First author: Alexandra Murar Co-author: Andreia Gherasâm.
1 MMS/Mass Coalition Program, Nov. 4, 2008 Patients with AF: Who Should be on Warfarin? Daniel E. Singer, MD Massachusetts General Hospital Harvard Medical.
Aspirin Resistance: Significance, Detection and Clinical Management of This Real Phenomenon Webcast May 10 th, 2004 Sponsored by.
Update in ESC: Dabigatran among OAC
The use of ELIQUIS® (apixaban) in various clinical populations
ATRIAL FIBRILLATION Dr ABHAY BAJPAI
Treatment of Atrial Fibrillation M Samson – PGY-2 Riverside Campus July 17, 2015 Academic Day.
Presented by Renato D. Lopes, MD, PhD, Duke Clinical Research Institute, Duke University, USA for the ARISTOTLE investigators. Efficacy and Safety of Apixaban.
CHADS 2 -> CHA 2 DS 2 VASc. CHA2DS2-VASc Risk Score CHF or LVEF < 40% 1 Hypertension1 Age > 752 Diabetes1 Stroke/TIA/ Thromboembolism 2 Vascular Disease.
CHADS, SHMADS: What’s All This About Anticoagulation? COPYRIGHT © 2016, ALL RIGHTS RESERVED From the Publishers of.
Case study - patient presenting with newly diagnosed NVAF with prior CAD Full Prescribing Information is provided at the end of this presentation EUAPI581k;
1 Risk/Benefit Assessment Jeremy N. Ruskin, M.D. Director, Cardiac Arrhythmia Services Massachusetts General Hospital.
Is there a future role for warfarin in stroke prevention for NVAF in 2014 EUAPI581f, April 2014 Full Prescribing Information is provided at the end of.
The Case for Rate Control: In the Management of Atrial Fibrillation Charles W. Clogston, M.D. Cardiologist CHI St. Vincent Heart Clinic Arkansas April.
Antithrombotic Therapy in Atrial Fibrillation Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention of Thrombosis,
Bleeding After Initiation of Multiple Antithrombotic Drugs, Including Triple Therapy, in Atrial Fibrillation Patients Following Myocardial Infarction and.
Stroke Local Pharmacy Group meeting 7 th May 2013 Dr. Lucy Sykes.
Atrial Fibrillation Jay H. Lee, MD Denver Health Medical Center Wednesday 2 July 2008.
Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACC/AHA/ESC 2006 Guidelines for the Management of.
Date of download: 7/10/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Choice of Antithrombotic Therapy for Stroke Prevention.
Postulated Association Between AF and Stroke
Case 66 year old male with PMH of HTN, DM, ESRD on renal replacement TIW, stroke in 2011 with right side residual weakness, atrial fibrillation, currently.
Antithrombotic Therapy in Atrial Fibrillation
Screening and diagnosis of AF and stratifying stroke risk
No evidence that AF type significantly impacts stroke risk
Management of Atrial Fibrillation
Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control 
Stroke secondary prevention
Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Prevention of Stroke and Systemic Thromboembolism in Atrial Fibrillation and Flutter 
The CHA(2)DS2-(VASc) stroke risk and HAS-BLED bleeding risk index are calculated by totalling the scores for each risk factor present.68–71 The lower graph.
Presentation transcript:

Prevention of thromboembolism in AF ACC/AHA/ESC Guidelines Jin-Bae Kim, MD, PhD Arrhythmia Service, Division of Cardiology Cardiovascular Center, Kyung Hee Univ Hospital

Atrial Fibrillation (AF ) : 1. A supraventricular tachyarrhythmia characterized by uncoordinated atrial activation with consequent deterioration of atrial mechanical function. 2. On ECG, AF is described by the replacement of consistent P waves by rapid oscillations or fibrillatory waves that vary in size, shape, and timing, associated with an irregular, frequently rapid ventricular response when AV conduction is intact. DEFINITION :

Classification: Paroxysmal AF: patient has had 2 or more episodes ( recurrent AF ) and the arrhythmia terminates spontaneously. Persistent AF: recurrent AF with sustained arrhythmia Permanent AF: long-standing AF ( e.g. greater than 1 year) in which cardioversion had not been indicated or attempted.

Patterns of atrial fibrillation First detected 1. Paroxysmal (Self-terminating) 2. Persistent (Not self-terminating) 3. Permanent 1. less than 7d (most ≤ 24hrs) 2. more than 7d CASE III-16-4

1. Maintenance of sinus rhythm 2. Control of rapid ventricular rate 3. Prevention of thromboembolism Therapeutic Goals CASE III-16-6

Thromboembolic Events Control Patients in AF Trials Cerebral 49 (91%) Systemic 5 (9%)

Thromboembolic Events - Mechanism Thrombus formation begins with Virchow’s triad of stasis, endothelial dysfunction, and a hypercoagulable state. Stunning of the LAA seems responsible for an increased risk of thromboembolic events after successful cardioversion, regardless of whether the method is electrical, pharmacological, or spontaneous. Decreased flow within the LA/LAA during AF has been associated with spontaneous echo contrast (SEC), thrombusformation, and embolic events.

Thromboembolic Events - Mechanism This phenomenon relates to fibrinogen-mediated erythrocyte aggregation and is not resolved by anticoagulation. Because the pathophysiology of thromboembolism in patients with AF is uncertain, the mechanisms linking risk factors to ischemic stroke in patients with AF are incompletely defined.

AFFIRM Stroke Events P=.79 P=.73 P=.68 P=.93 The AFFIRM Investigators. N Engl J Med. 2002;347: Percent Ischemic stroke ICHSDH/SAHAll stroke RateRhythm

Less Validated or Weaker Risk Factors Moderate-Risk Factors High-Risk Factors Female genderAge ≥ 75 yPrevious stroke, TIA or embolism Age 65 to 74 yHypertensionMitral stenosis Coronary artery disease Heart FailureProsthetic heart valve ThyrotoxicosisLVEF ≤ 35% Diabetes mellitus Classification of Stroke Risk Factors Fuster V. et.al. JACC 2006

Antithrombotic therapy for patients with atrial fibrillation Risk CategoryRecommended Therapy No risk factorsAspirin, 81 to 325 mg daily One moderate-risk factorAspirin, 81 to 325 mg daily, or Warfarin (INR 2.0 to 3.0, target 2.5) Any high-risk factor or ≥ 2 moderate risk factor Warfarin (INR 2.0 to 3.0, target 2.5) Fuster V. et.al. JACC 2006

CHA 2 DS 2 VASc score and stroke rate Risk factors ≥ 75 yrs old(2) Previous stroke, TIA Thromboemolism(2) CHF(1) HT(1) DM(1) Vascular disease(1) 65~74 세 (1) Female(1) Adjusted stroke rate according to CHA 2 DS 2 VASc score CHA 2 DS 2 VASc score Patients(n=7329) Adjusted stroke rate(%/year) 010% % % % % % % % % % Camm AJ, et al. Eur Heart J 2010

ACTIVE A and W: Stroke Rates and Risk Reductions TreatmentVKAC+AAspirin ACTIVE W (Rate per year) ACTIVE A (Rate per year) RRR versus Aspirin-58%-28%-- RRR versus C+A -42% --

International Normalized Ratio Odén A, et. al. Thromb Res Ischemic Stroke Intracranial bleeding

Doubling of the rate of intracranial hemorrhage when the INR exceeds % increases in the rate of stroke when the INR is less than 2.0

HAS-BLED bleeding risk score bleeding risk score Elderly > 65yrs old(1) Stroke(1) Hypertension(1) Abnormal renal function(1) Abnormal liver function(1) Vascular disease(1) Bleeding(1) Labile INRs(1) Drugs(1) Alcohol(1) LetterClinical characteristic a Points awarded HHypertension1 A Abnormal renal and liver Function(1 point each) 1 or 2 SStroke1 BBleeding1 LLabile INRs1 EElderly(e.g.age>65years)1 D Drugs or alcohol(1 point each) 1 or 2 Maximum 9 points Pisters R, at al, Chest 2010